Extension study of EVP6124 in patients with Schizophrenia

• Research type

  Research Study

• Full title

  A Multicenter 26-Week Extension Study to Evaluate the Safety and Clinical Effects of Prolonged Exposure to 1 and 2 mg Doses of EVP-6124, an Alpha-7 Nicotinic Acetylcholine Receptor Agonist, as an Adjunctive Pro-cognitive Treatment in Subjects with Schizophrenia on Chronic Stable Atypical Antipsychotic Therapy

• IRAS ID

  131838

• Contact name

  Sukhi Shergill

• Contact email

  sukhi.shergill@kcl.ac.uk

• Sponsor organisation

  EnVivo Pharmaceuticals, Inc.

• Eudract number

  2012-003228-19

• Research summary

  Schizophrenia comes with a wide range of symptoms including moderate to severe decreases in a patient’s cognitive ability (A group of mental functions like attention, problem solving, memory and language)
  There are currently no treatments available to treat this decrease in cognitive ability however the objective of this study is to assess the long-term safety and the extended clinical effects of two doses of EVP-6124 (1mg and 2mg), taken once daily as a pro-cognitive treatment when taken in conjunction with anti-psychotic therapy in subjects who received EVP-6124 in both the pivotal and extension study.

• REC name

  London - Fulham Research Ethics Committee

• REC reference

  14/LO/0359

• Date of REC Opinion

  22 Apr 2014

• REC opinion

  Further Information Favourable Opinion